| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10637-009-9310-0 |
| P698 | PubMed publication ID | 19756376 |
| P50 | author | Yeul Hong Kim | Q98617374 |
| P2093 | author name string | Jae Hong Seo | |
| Ae-Ree Kim | |||
| Jun Suk Kim | |||
| Kyong Hwa Park | |||
| Eun Sook Lee | |||
| Dae Sik Yang | |||
| Jae-Bok Lee | |||
| Ok Hee Woo | |||
| Sang Uk Woo | |||
| P2860 | cites work | Tumor angiogenesis: therapeutic implications | Q27860595 |
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer | Q28183621 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 | ||
| Role of vascular endothelial growth factor in the regulation of angiogenesis | Q33723796 | ||
| The impact of expression profiling on prognostic and predictive testing in breast cancer | Q35769768 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 | ||
| Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer | Q71261788 | ||
| Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment | Q72883776 | ||
| Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation | Q83194112 | ||
| P433 | issue | 1 | |
| P921 | main subject | bevacizumab | Q413299 |
| meta-analysis | Q815382 | ||
| metastatic breast cancer | Q12859063 | ||
| P304 | page(s) | 182-188 | |
| P577 | publication date | 2009-09-16 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials | |
| P478 | volume | 29 |
| Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
| Q36248498 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence |
| Q31157714 | Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. |
| Q30657829 | First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. |
| Q37392845 | GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis |
| Q35061280 | Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials |
| Q54374887 | The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials. |
| Q53167121 | Treatment of bevacizumab-induced hypertension by amlodipine. |
| Q57140329 | Triple-negative breast cancer |
| Q24202199 | Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer |
Search more.